Q-omics provides the consensus-scored PLPP5 profile across patient tissues and cancer cell-line models. PLPP5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PLPP5 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, PLPP5 RNA expression shows 20,244 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, LUAD, and ACC as cancer lineages where PLPP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLPP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLPP5 survival associations across molecular data types. PLPP5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLPP5 RNA expression–survival associations across cancer types. High PLPP5 expression shows unfavorable associations in KIRP, UVM, KIRC and ACC, but favorable associations in UCEC and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PLPP5 RNA expression.
This table summarizes PLPP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for PLPP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLPP5 shows lower tumor expression in KICH and higher tumor expression in LUAD, BLCA, LUSC, BRCA and UCEC. The LUAD box plot shows higher PLPP5 RNA expression in tumor versus normal tissue (log2 FC = +1.016, t-test p < 0.001).
This table shows molecular features associated with PLPP5 in patient tissues and cancer cell lines. In patient samples, PLPP5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PLPP5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
